Scleromyxedema. A chronic progressive systemic disease;Skleromyxödem: Eine chronisch progressive systemerkrankung

Zeitschrift fur Rheumatologie

Volumn 71, Issue 6, 2012, Pages 504-514

  Kreuter, A ^a   Stucker M ^a   Kolios, A G A ^a   Altmeyer, P ^a   Mollenhoff K ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Bortezomib; Intravenous immunoglobulins; Lichen myxedematosus; Monoclonal gammopathy; Scleromyxedema

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN LAMBDA CHAIN;

ARTHRITIS; ARTICLE; CASE REPORT; DRUG PULSE THERAPY; ESOPHAGUS MOTILITY; FEMALE; HUMAN; LUNG FIBROSIS; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MYOSITIS; POLYNEUROPATHY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCLEROMYXEDEMA;

ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLEROMYXEDEMA;

EID: 84866928400     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-012-0997-5     Document Type: Article

References (70)

1. Dubreuilh W (1906) Fibromes miliaires folliculai-res: sclerodemie consecutive. Ann Dermatol Syph 37:569-572
2. Reitmann K (1908) Über eine eigenartige, der Skle-rodermie nahestehende Affektion. Arch Dermatol Syph 92:417-424
3. Montgomery H, Underwood LJ (1953) Lichen my-xedematosus (differentiation from cutaneous my-xedemas or mucoid states). J Invest Dermatol 20:213-236
4. Gottron HA (1954) Skleromyxödem (eine eigen-artige Erscheinungsform von Myxothesauroder-mie). Arch Dermatol Syph 199:71-91
5. Pomann JJ, Rudner EJ (2003) Scleromyxedema revisited. Int J Dermatol 42:31-35
6. Rongioletti F, Rebora A (2001) Updated classification of papular mucinosis, lichen myxedemato-sus, and scleromyxedema. J Am Acad Dermatol 44:273-281
7. Fabri M, Hunzelmann N (2007) Differential diagnosis of scleroderma and pseudoscleroderma. J Dtsch Dermatol Ges 5:977-984
8. Yaron M, Yaron I, Yust I, Brenner S (1985) Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 12:171-175
9. Ferrarini M, Helfrich DJ, Walker ER et al (1989) Scle-romyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibro-blasts. J Rheumatol 16:837-841
10. Harper RA, Rispler J (1978) Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 199:545-547
11. Bata-Csorgo Z, Husz S, Foldes M et al (1999) Sclero-myxedema. J Am Acad Dermatol 41:343-346
12. Kulczycki A, Nelson M, Eisen A, Heffernan M (2003) Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol 149:1276-1281
13. Godby A, Bergstresser PR, Chaker B, Pandya AG (1998) Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol 38:289-294
14. Dinneen AM, Dicken CH (1995) Scleromyxedema. J Am Acad Dermatol 33:37-43
15. Gabriel SE, Perry HO, Oleson GB, Bowles CA (1988) Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore) 67:58-65
16. Blum M, Wigley FM, Hummers LK (2008) Scleromy-xedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglo-bulin (IVIG). Medicine (Baltimore) 87:10-20
17. Webster GF, Matsuoka LY, Burchmore D (1993) The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol 28:105-108
18. McCuistion CH, Schoch EP Jr (1956) Autopsy findings in lichen myxedematosus. Arch Dermatol 74:259-262
19. River Y, Levy I, Gilead L et al (1996) Fever, convulsions and coma in scleromyxedema: a "dermatoneu-ro syndrome". Neurology 46(6):1778-1799
20. Gonzalez J, Palangio M, Schwartz J et al (2000) Scleromyxedema with dermatoneuro syndrome. J Am Acad Dermatol 42:927-928
21. Rey JB, Luria RB (2009) Treatment of scleromyxe-dema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 60:1037-1041
22. Yu RK, Ariga T (1998) The role of glycosphingoli-pids in neurological disorders. Mechanisms of immune action. Ann N Y Acad Sci 845:285-306
23. Farr PM, Ive FA (1984) PUVA treatment of sclero-myxoedema. Br J Dermatol 110:347-350
24. Kaufman D, Truha A P, Roenigk HH Jr (1987) Sclero-myxedema: systemic manifestations and cosmetic improvement with dermabrasion. Cutis 39:321-324
25. Milam CP, Cohen LE, Fenske NA, Ling NS (1988) Scleromyxedema: therapeutic response to iso-tretinoin in three patients. J Am Acad Dermatol 19:469-477
26. Hisler BM, Savoy LB, Hashimoto K (1991) Improvement of scleromyxedema associated with isotreti-noin therapy. J Am Acad Dermatol 24:854-857
27. Tschen JA, Chang JR (1999) Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 40:303-307
28. Cohen AM, Hodar E, David M et al (1996) Beneficial effect of granulocyte-colony stimulating factor in scleromyxedema associated with severe idiopathic neutropenia. Br J Dermatol 135:626-629
29. Lowe NJ, Dufton PA, Hunter RD, Vickers CF (1982) Electron-beam treatment of scleromyxoedema. Br J Dermatol 106:449-453
30. Berkson M, Lazarus GS, Uberti-Benz M, Rook AH (1991) Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol 25:724
31. Howsden SM, Herndon JH Jr, Freeman RG (1975) Lich myxedematosus: a dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol 111:1325-1330
32. Jessen RT, Straight M, Becker LE (1978) Lichen my-xedematosus: treatment with cyclophosphamide. Int J Dermatol 17:833-839
33. Verity MA, Toop J, McAdam L P, Pearson CM (1978) Scleromyxedema myopathy: histochemical and electron microscopic observations. Am J Clin Pat-hol 69:446-451
34. McAdam LP, Pearson CM, Pitts WH et al (1977) Papular mucinosis with myopathy, arthritis, and eosi-nophilia: a histopathologic study. Arthritis Rheum 20:989-996
35. Keong CH, Asaka Y, Fukuro S et al (1990) Successful treatment of scleromyxedema with plasmaphere-sis and immunosuppression. J Am Acad Dermatol 22:842-844
36. Feldman P, Shapiro L, Pick AI, Slatkin MH (1969) Scleromyxedema: a dramatic response to melpha-lan (in German). Arch Dermatol 99:51-56
37. Harris RB, Perry HO, Kyle RA, Winkelmann RK (1979) Treatment of scleromyxedema with mel-phalan. Arch Dermatol 115:295-299
38. Horn KB, Horn MA, Swan J et al (2004) A complete and durable clinical response to high-dose de-xamethasone in a patient with scleromyxedema. J Am Acad Dermatol 51:120-123
39. Kreuter A, Altmeyer P (2005) High-dose dexamet-hasone in scleromyxedema: report of 2 additional cases. J Am Acad Dermatol 53:739-740
40. Wojas-Pelc A, Blaszczyk M, Glińska M, Jablońska S (2005) Tumorous variant of scleromyxedema. Successful therapy with intravenous immuno-globu-lins. J Eur Acad Dermatol Venereol 19:462-465
41. Majeski C, Taher M, Grewal P et al (2005) Combination oral prednisone and intravenous immunoglo-bulin in the treatment of scleromyxedema. J Cutan Med Surg 9:99-104
42. Topf S, Simon M Jr, Schell H, Lüftl M (2007) Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin. Hautarzt 58:525-528
43. Gholam P, Hartmann M, Enk A (2007) Arndt-Gott-ron scleromyxoedema: successful therapy with intravenous immunoglobulins. Br J Dermatol 157:1058-1060
44. Efthimiou P, Blanco M (2008) Intravenous gam-maglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxe-dema: case report and discussion of the literature. Semin Arthritis Rheum 38:188-194
45. Lister RK, Jolles S, Whittaker S et al (2000) Sclero-myxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43:403-408
46. Körber A, Franckson T, Grabbe S, Dissemond J (2007) Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobu-lin. J Eur Acad Dermatol Venereol 21:553-554
47. Binitha MP, Nandakumar G, Thomas D (2008) Suspected cardiac toxicity to intravenous immunog-lobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol 74:248-250
48. Lopez L, Wierzbicka-Hainaut E, Villers A, Guillet G (2009) Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema. Ann Dermatol Venereol 136:330-336
49. Manousaridis I, Loeser C, Goerdt S, Hassel JC (2010) Managing scleromyxedema with intravenous immunoglobulin: acute worsening of sclero-myxedema with biclonal gammopathy. Acta Der-matovenerol Alp Panonica Adriat 19:15-19
50. Feasel AM, Donato ML, Duvic M (2001) Complete remission of scleromyxedema following auto-logous stem cell transplantation. Arch Dermatol 137:1071-1072
51. Donato ML, Feasel AM, Weber DM et al (2006) Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107:463-466
52. Lacy MQ, Hogan WJ, Gertz MA et al (2005) Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 141:1277-1282
53. Illa I, Torre C de la, Rojas-Garcia R et al (2006) Steady remission of scleromyxedema 3 years after au-tologous stem cell transplantation: an in vivo and in vitro study. Blood 108:773-774
54. Iranzo P, López-Lerma I, Bladé J et al (2007) Scle-romyxoedema treated with autologous stem cell transplantation. J Eur Acad Dermatol Venereol 21:129-130
55. Ataergin S, Arpaci F, Demiriz M, Ozet A (2008) Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. Am J Clin Dermatol 9:271-273
56. Cheng T, Gnanakumar V, Hegedus C, Stewart DA (2008) Complete and durable remission in a patient with life-threatening scleromyxedema treated with high-dose melphalan and BU with auto-SCT. Bone Marrow Transplant 42:215-217
57. Bos R, Waal EG de, Kuiper H et al (2011) Thalidomi-de and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology (Oxford) 50:1925-1926
58. Caradonna S, Jacobe H (2004) Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 140:277-280
59. Sansbury JC, Cocuroccia B, Jorizzo JL et al (2004) Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 51:126-131
60. Jacob SE, Fien S, Kerdel FA (2006) Scleromyxede-ma, a positive effect with thalidomide. Dermatology 213:150-152
61. Thyssen J P, Zachariae C, Menné T (2006) Successful treatment of scleromyxedema using thalidomide. J Eur Acad Dermatol Venereol 20:1396-1397
62. Amini-Adle M, Thieulent N, Dalle S et al (2007) Scleromyxedema: successful treatment with thali-domide in two patients. Dermatology 214:58-60
63. Martins A, Paiva Lopes MJ et al (2008) Scleromyxe-dema-thalidomide therapy. J Eur Acad Dermatol Venereol 22:622-624
64. Wu MY, Hong JB, Yang CC et al (2009) Scleromy-xedema with myopathy was successfully treated by thalidomide. J Eur Acad Dermatol Venereol 23:189-190
65. Peter LM, Ammoury A, Chiavassa-Gandois H et al (2008) Scleromyxoedema with associated peripheral neuropathy: successful treatment with thalido-mide. Clin Exp Dermatol 33:606-610
66. Le Moigne M, Mazereeuw-Hautier J, Bonnetblanc JM et al (2010) Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study. Ann Dermatol Venereol 137:782-788
67. Laimer M, Namberger K, Massone C et al (2009) Vincristine, idarubicin, dexamethasone and thali-domide in scleromyxoedema. Acta Derm Venereol 89:631-635
68. Sillard L, Passeron T, Cardot-Leccia N et al (2010) Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema. Ann Dermatol Vene-reol 137:48-52
69. Migkou M, Gkotzamanidou M, Terpos E et al (2011) Response to bortezomib of a patient with sclero-myxedema refractory to other therapies. Leuk Res 35:209-211
70. Fett NM, Toporcer MB, Dalmau J et al (2011) Scle-romyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J He-matol 86:893-896ww